Aura Biosciences (NASDAQ:AURA) CTO Sells $77,273.15 in Stock

Key Points

• Mark Plavsic, the CTO of Aura Biosciences, sold 12,169 shares of the company's stock for a total of $77,273.15, reducing his ownership by 5.81%.
• Aura Biosciences reported an EPS of ($0.47) for their last quarter, beating analyst expectations by $0.02, with a projected EPS of ($1.66) for the current year.
• Analysts have a consensus rating of "Moderate Buy" for Aura Biosciences, with a target price set at $22.00.

Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) CTO Mark Plavsic sold 12,169 shares of the firm's stock in a transaction on Thursday, October 16th. The shares were sold at an average price of $6.35, for a total value of $77,273.15. Following the transaction, the chief technology officer directly owned 197,287 shares in the company, valued at $1,252,772.45. This trade represents a 5.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Aura Biosciences Price Performance

Shares of AURA traded down $0.16 during trading hours on Thursday, reaching $6.19. 365,934 shares of the company's stock traded hands, compared to its average volume of 225,258. The firm has a market capitalization of $384.52 million, a price-to-earnings ratio of -3.16 and a beta of 0.45. Aura Biosciences, Inc. has a twelve month low of $4.34 and a twelve month high of $12.38. The business's fifty day simple moving average is $6.34 and its two-hundred day simple moving average is $6.17.

Aura Biosciences (NASDAQ:AURA - Get Free Report) last issued its quarterly earnings results on Wednesday, August 13th. The company reported ($0.47) EPS for the quarter, beating analysts' consensus estimates of ($0.49) by $0.02. On average, equities research analysts expect that Aura Biosciences, Inc. will post -1.66 EPS for the current year.

Hedge Funds Weigh In On Aura Biosciences

Large investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC boosted its holdings in shares of Aura Biosciences by 49.3% during the second quarter. Tower Research Capital LLC TRC now owns 6,372 shares of the company's stock worth $40,000 after purchasing an additional 2,104 shares during the period. GAMMA Investing LLC lifted its holdings in shares of Aura Biosciences by 5,766.9% during the 1st quarter. GAMMA Investing LLC now owns 9,739 shares of the company's stock valued at $57,000 after buying an additional 9,573 shares during the last quarter. Invesco Ltd. acquired a new stake in Aura Biosciences in the 2nd quarter worth approximately $76,000. China Universal Asset Management Co. Ltd. lifted its holdings in Aura Biosciences by 24.3% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 12,453 shares of the company's stock worth $78,000 after purchasing an additional 2,434 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Aura Biosciences by 286.6% in the 2nd quarter. BNP Paribas Financial Markets now owns 13,499 shares of the company's stock worth $85,000 after purchasing an additional 10,007 shares during the last quarter. Institutional investors and hedge funds own 96.75% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on AURA shares. HC Wainwright restated a "buy" rating and set a $22.00 target price on shares of Aura Biosciences in a report on Wednesday, August 13th. Zacks Research upgraded Aura Biosciences from a "strong sell" rating to a "hold" rating in a report on Tuesday, August 19th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Aura Biosciences in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $22.00.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.